NASDAQ (usa) |
![]() |
6715.56 | -12.11 | -0.18% |
FTSE 100 (london) |
![]() |
7487.96 | -5.12 | -0.07% |
DAX (german) |
![]() |
13465.51 | 235.94 | 1.78% |
NIKKEI 225 (japan) |
![]() |
22420.08 | 408.47 | 1.86% |
Hang - Seng (hong kong) |
![]() |
28594.06 | 348.52 | 1.23% |
NIFTY - 50 (india) |
![]() |
10605.15 | -35.80 | -0.34% |
Straits Times (singapore) |
![]() |
3391.61 | 17.53 | 0.52% |
KOSPI (korea) |
![]() |
2556.47 | 33.04 | 1.31% |
All Ordinaries (australia) |
![]() |
6005.30 | 28.90 | 0.48% |
BOVESPA (brazil) |
![]() |
74092.76 | -215.73 | -0.29% |
IsoRay, Inc. (AMEX: ISR)
ISR Technical Analysis
5
As on 31st Oct 2017 ISR Share Price closed @ 0.45 and we RECOMMEND Strong Sell for LONG-TERM with Stoploss of 0.57 & Strong Sell for SHORT-TERM with Stoploss of 0.53 we also expect STOCK to react on Following IMPORTANT LEVELS. |
ISR Share Price
Open | 0.45 | Change | Price | % |
High | 0.47 | 1 Day | 0.00 | 0.00 |
Low | 0.43 | 1 Week | 0.00 | 0.00 |
Close | 0.45 | 1 Month | -0.10 | -18.18 |
Volume | 259798 | 1 Year | -0.12 | -21.05 |
52 Week High 0.70 | 52 Week Low 0.40 |
AMEX USA Most Active Stocks
PAL | 0.05 | -50.00% |
NGD | 3.29 | -6.80% |
RBY | 0.03 | -70.00% |
LODE | 0.12 | -7.69% |
PBTH | 8.23 | 0.37% |
GGR | 0.02 | 100.00% |
VTG | 0.05 | -16.67% |
SYRG | 8.13 | 0.87% |
GSX | 0.02 | 0.00% |
SHZ | 0.10 | -16.67% |
AMEX USA Top Gainers Stocks
AMEX USA Top Losers Stocks
ISR Daily Charts |
ISR Intraday Charts |
Whats New @ Bazaartrend |
ISR Free Analysis |
|
ISR Important Levels Intraday
SUPPORT | 0.00 |
SUPPORT | 0.00 |
RESISTANCE | 0.49 |
RESISTANCE | 0.47 |
SUPPORT | 0.43 |
SUPPORT | 0.41 |
SUPPORT | 0.00 |
SUPPORT | 0.00 |
ISR Target for Month February
4th UP TARGET | 0.76 |
3rd UP TARGET | 0.66 |
2nd UP TARGET | 0.6 |
1st UP TARGET | 0.54 |
1st DOWN TARGET | 0.36 |
2nd DOWN TARGET | 0.3 |
3rd DOWN TARGET | 0.24 |
4th DOWN TARGET | 0.14 |
ISR Weekly Target
4th UP TARGET | 0.00 |
3rd UP TARGET | 0.00 |
2nd UP TARGET | 0.00 |
1st UP TARGET | 0.00 |
1st DOWN TARGET | 0.00 |
2nd DOWN TARGET | 0.00 |
3rd DOWN TARGET | 0.00 |
4th DOWN TARGET | 0.00 |
ISR Target for Year 2019
4th UP TARGET | 0 |
3rd UP TARGET | 0 |
2nd UP TARGET | 0 |
1st UP TARGET | 0 |
1st DOWN TARGET | 0 |
2nd DOWN TARGET | 0 |
3rd DOWN TARGET | 0 |
4th DOWN TARGET | 0 |
IsoRay, Inc. ( AMEX USA Symbol : ISR )
Sector : Healthcare And Other Stocks in Same Sector
Sector : Healthcare And Other Stocks in Same Sector
ISR Other Details
Segment | EQ | |
Market Capital | 20927304.00 | |
Sector | Healthcare | |
Industry | Medical Instruments & Supplies | |
Offical website | http://www.isoray.com |
ISR Address
![]() |
350 Hills Street Suite 106 Richland, WA 99354 United States Phone: 509-375-1202 |
ISR Latest News
ISR Business Profile
IsoRay, Inc develops, manufactures, and sells isotope-based medical products and devices for the treatment of cancer and other malignant diseases primarily in the United States. The company produces Proxcelan Cesium-131 brachytherapy seeds that are used for the treatment of prostate, lung, head and neck, colorectal, brain, pelvic/abdominal, and gynecological cancers, as well as ocular melanoma. It also offers GliaSite radiation therapy system, a balloon catheter device, which is used to treat brain cancer, including primary and recurrent gliomas and metastic brain tumors. The company is based in Richland, Washington.
© 2005-2019 BazaarTrend.com All rights reserved.
Data and information is provided for informational purposes only, and is not intended for trading purposes.
Neither BazaarTrend.com website nor any of its promoters shall be liable for any errors
or delays in the content, or for any actions taken in reliance thereon. Your use of this website constitutes
acceptance of our Terms Of Service
Data and information is provided for informational purposes only, and is not intended for trading purposes.
Neither BazaarTrend.com website nor any of its promoters shall be liable for any errors
or delays in the content, or for any actions taken in reliance thereon. Your use of this website constitutes
acceptance of our Terms Of Service